Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer

Indian Journal of Cancer

Volumn 46, Issue 3, 2009, Pages 194-202

  Shah, F D ^a   Shukla, S N ^a   Shah, P M ^a   Shukla, H K ^a   Patel, P S ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Breast cancer; MMP 2; MMP 9; Zymography

Indexed keywords

GELATINASE A; GELATINASE B;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLIMACTERIUM; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; PREMENOPAUSE; RECEIVER OPERATING CHARACTERISTIC; ZYMOGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 67651152864     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.52953     Document Type: Article

References (30)

1. Parkin DM, Bray F, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Hanahan D, Weinberg RA.The hallmarks of cancer. Cell 2000;100:57-70.
3. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
4. Strenlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev cell Dev Biol 2001;17:463-516.
5. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinases-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-62.
6. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, Lee CY, et al. Relationship between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta 2006;371:92-6.
7. Ramacle AG, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM, et al. Assay of matrix metalloproteinases types 1,2,3 and 9 in breast cancer. Br J Cancer 1998;77:926-31.
8. Lowry OH, Rosebrough NJ, Farr AL, Randali RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
9. Lorenzo JA, Pilbeam CC, Kalinowski JF, Hibbs MS. Production of both 92 and 72 kDa gelatinase by bone cells. Matrix 1992;12:282-90.
10. Garbett EA, Reed MW, Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer 1999;81:287-93.
11. Hrabec E, Strek M, Nowak D, Greger J, Suwalski M, Hrabec Z. Activity of type IV collagenases (MMP-2 and MMP-9) in primary pulmonary carcinomas: a quantitative analysis. J Cancer Res Clin Oncol 2002;128:197-204.
12. Baker EA, Leaper DJ. The plasminogen activator and matrix metal-loproteinase systems in colorectal cancer: Relationship to tumour pathology. Eur J Cancer 2003;39:981-8.
13. Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, Kos J, et al. Enhanced gelatinase urinary activity (Matrix metalloproteinases 2 and 9) are associated with early stage bladder carcinoma: A comparison with clinically used tumor markers. Clin Cancer Res 2000;7:445-7.
14. Schutz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, Witte-kind C. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cells carcinoma of the lung. Tumor Biol 2002;23:179-84.
15. Hong SD, Hong SP, Lee JI, Lim CY. Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinoma with regard to the metastatic potential. Oral Oncol 2000;36: 207-13.
16. Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM, et al. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma. J Sur Oncol 2005;90:81-8.
17. Polette M, Clavel C, Cockett M, Girod de Bentzmann S, Murphy G, Birembaut P. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitors in breast pathology. Invasion Metastasis 1993;13:31-7.
18. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remacle A, et al. Gelitinase A expression and localization in human breast cancers. An In situ hybridization study and immunohistochemical detection using confocal microscopy. Virchow Arch 1994;424:641-5.
19. Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG. Independent expression and cellular processing of Mr72000 type IV collagenase and interstitial collagenase in human tumourigenic cell lines. Cancer Res 1990;50:6184-91.
20. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinases family members in breast cancer represents a tumour induced host response. Am J Pathol 1996;149:273-82.
21. Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffe E, et al. Circulating 92- Kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma. Cancer 2002;94: 1483-91.
22. Schmidt M, Polednik C, Hoppe F. Proteolytic patterns of head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 1999;256:346-50.
23. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee JU, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642-50.
24. Takashi M, Oka N, Naroda T, Nishitami MA, Kanda K, Kanayama HO, et al. Prognostic signifi cance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol 2002;10:531-8.
25. Schrohl AS, Holten Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. Tumor tissue levels of Tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004;10:2289-98.
26. Talvensari-Mattila A, Pakko P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node positive breast carcinoma. Breast Cancer Res Treat 1999;58:287-93.
27. Talvensari-Mattila A, Pakko P, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinases-2 is associated with the risk for a relapse in postmenopausal patients with node positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res Treat 2001;65:55-61.
28. Hirvonen R, Talvensari-Mattila A, Pakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinases-2 (MMP-2) in T (1-2) N0 breast carcinoma. Breast Cancer Res Treat 2003;77:85-91.
29. Daidone MG, Silvestrini R, D'errico A, Di Fronzo G, Benini E, Mancini AM, et al. Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 1991;48: 529-32.
30. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004;88:75-85.